Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Four-year effectiveness, safety and drug retention rate of secukinumab in psoriatic arthritis: a real-life Italian multicenter cohort

Fig. 1

A-B Minimal disease activity (MDA) (percentage, %) of overall population and after their subdivision in two groups, according to the DMARD treatment line (naïve patients vs non-naïve patients) (A) and after their subdivision in three groups, according to number of comorbidities (0 comorbidities, 1–3 comorbidities, > 3 comorbidities) (B). Legend: n, number of evaluated patients; naïve: naïve to bDMARDs; non-naïve: bDMARDs failure

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us